Sponsors (39)
The bill strengthens testing, reporting, and oversight to better protect infants from contaminated formula, but it raises costs, risks short-term supply disruptions, and creates regulatory and confidentiality strains.
Parents and infants: Mandatory increased testing, faster manufacturer-to-FDA reporting and rapid FDA-to-Congress notification will reduce the chance that contaminated infant formula reaches babies and speed government awareness of hazards.
Hospitals and public health systems (and indirectly parents): More consistent inspection/compliance standards across domestic and imported formula plus retention of positive-test records will strengthen oversight, aid investigations, and improve the ability to trace contamination sources.
Parents and caregivers: Stricter testing and rapid reporting could lead to more recalls or product holds and thus reduce short-term availability of infant formula.
Infant formula manufacturers (and consumers): New testing, recordkeeping, and rapid-reporting requirements will raise compliance costs that may be passed on to consumers, increasing prices.
Hospitals and FDA operations: A 90-day deadline for issuing final regulations may strain FDA resources and lead to rushed rulemaking or implementation challenges.
Based on analysis of 2 sections of legislative text.
Requires FDA to mandate pathogen and environmental testing, one-day reporting, record retention, and uniform inspection standards for all infant formula; final rules due in 90 days.
Official title: To amend the Federal Food, Drug, and Cosmetic Act to establish standardized pathogen and microorganism testing of infant formula products and manufacturing facilities, to mandate notification of specific positive tests and inspection classifications, and for other purposes.
Introduced March 9, 2026 by Rosa L. Delauro · Last progress March 9, 2026
Requires the FDA to strengthen infant formula manufacturing rules by mandating pathogen and environmental testing of facilities and finished products, one-business-day reporting of positive results to FDA, retention of records, and uniform inspection and compliance standards for all formula regardless of origin. The bill directs the FDA to include a required test list (explicitly including Clostridium botulinum), set environmental testing frequencies for facility zones, and issue final regulations within 90 days of enactment. Also requires FDA to notify specified House and Senate committees within one business day when it receives a manufacturer’s positive finished-product test result or issues an inspection classification equivalent to “official action indicated.”